NSCLC — Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
Citation(s)
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) - A Multicentric Phase II Study in Patients With TKI-resistant EGFR-mutated Lung Cancer Exhibiting Early Metabolic Response to Osimertinib